全文获取类型
收费全文 | 135643篇 |
免费 | 10952篇 |
国内免费 | 3371篇 |
专业分类
耳鼻咽喉 | 2383篇 |
儿科学 | 7711篇 |
妇产科学 | 3913篇 |
基础医学 | 16487篇 |
口腔科学 | 1937篇 |
临床医学 | 14712篇 |
内科学 | 23122篇 |
皮肤病学 | 2394篇 |
神经病学 | 13601篇 |
特种医学 | 2947篇 |
外国民族医学 | 3篇 |
外科学 | 11939篇 |
综合类 | 18602篇 |
现状与发展 | 16篇 |
预防医学 | 7718篇 |
眼科学 | 2258篇 |
药学 | 6938篇 |
55篇 | |
中国医学 | 11323篇 |
肿瘤学 | 1907篇 |
出版年
2024年 | 296篇 |
2023年 | 2404篇 |
2022年 | 3948篇 |
2021年 | 6817篇 |
2020年 | 6268篇 |
2019年 | 4950篇 |
2018年 | 4938篇 |
2017年 | 5097篇 |
2016年 | 5148篇 |
2015年 | 4862篇 |
2014年 | 9307篇 |
2013年 | 9678篇 |
2012年 | 7562篇 |
2011年 | 8703篇 |
2010年 | 6901篇 |
2009年 | 6782篇 |
2008年 | 6587篇 |
2007年 | 6589篇 |
2006年 | 5904篇 |
2005年 | 4900篇 |
2004年 | 4138篇 |
2003年 | 3699篇 |
2002年 | 2612篇 |
2001年 | 2361篇 |
2000年 | 2048篇 |
1999年 | 1909篇 |
1998年 | 1587篇 |
1997年 | 1449篇 |
1996年 | 1345篇 |
1995年 | 1336篇 |
1994年 | 1118篇 |
1993年 | 1023篇 |
1992年 | 939篇 |
1991年 | 691篇 |
1990年 | 644篇 |
1989年 | 545篇 |
1988年 | 545篇 |
1987年 | 490篇 |
1986年 | 435篇 |
1985年 | 580篇 |
1984年 | 496篇 |
1983年 | 319篇 |
1982年 | 415篇 |
1981年 | 366篇 |
1980年 | 317篇 |
1979年 | 252篇 |
1978年 | 174篇 |
1977年 | 131篇 |
1976年 | 104篇 |
1975年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
BackgroundPercutaneous endoscopic gastrostomy (PEG) is required for Levodopa/Carbidopa Intestinal Gel (LCIG) delivery in patients with advanced Parkinson's disease (PD) as well as for enteral feeding in a variety of neurological disorders. Buried Bumper Syndrome (BBS) is a serious complication of PEG. The frequency of BBS in patients receiving LCIG treatment has never been reported.ObjectivesTo compare the frequency of BBS in patients on LCIG treatment or on enteral feeding over the past 12 years and identify possible risk factors.MethodsWe reviewed prospectively recorded data from 2009 to 2020 on two case-series: LCIG-treated PD patients and non-PD patients on enteral nutrition. We identified all BBS incidences. Patients’ characteristics, clinical manifestations, BBS management, possible risk factors and outcomes were analyzed.ResultsDuring the 12 years, 35 PD patients underwent PEG insertion for LCIG infusion, and 123 non-PD patients for nutritional support. There were eight cases of BBS in six PD patients (17.1%). Six of them were effectively managed without treatment discontinuation. Of the enteral feeding patients, only one developed BBS (0.8%) (p < 0.001). We identified inappropriate PEG site aftercare, weight gain, early onset PD, longer survival, treatment duration, dementia and PEG system design as potential risk factors for BBS development.ConclusionsBBS occurs more frequently in LCIG patients than in patients receiving enteral feeding. If detected early, it can be successfully managed, and serious sequalae or treatment discontinuation can be avoided. Regular endoscopic follow-up visits of LCIG-treated patients and increased awareness in patients and clinicians are recommended. 相似文献
72.
73.
通过回顾分析我院2例确诊为胰岛素自身免疫综合征(IAS)患者的临床资料,并复习相关文献,总结发病机制及治疗方法,探讨IAS患者的临床特点,提高对低血糖症的诊治水平。 相似文献
74.
75.
76.
Regan E. Giesinger Adrianne R. Bischoff Patrick J. McNamara 《Congenital heart disease》2019,14(2):311-316
Ligation of a hemodynamically significant ductus arteriosus results in significant changes in loading conditions which have predictable consequences. Postligation cardiac syndrome, defined as hypotension requiring inotropic support and failure of oxygenation and ventilation, may occur 6‐12 hours following ligation due to left ventricular systolic and diastolic failure, respectively. Afterload is the primary driver of this decompensation. In this review, we describe the pathophysiological changes in loading conditions associated with postligation cardiac syndrome and other contributors to cardiovascular dysfunction following ductal ligation. We present strategies for perioperative optimization and a physiology‐based algorithm for postoperative management guided by targeted neonatal echocardiography. The use of these strategies to reduce the frequency of postligation deterioration may be an avenue to improve outcomes for neonates in this vulnerable patient population. 相似文献
77.
78.
79.
80.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献